V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10007661 | 10007733 | 1.82 | 79.3 | Palliative (P) | 2019-07-28 | 2019-07-28 | CABOZANTINIB | N | N | 10429904 | NILOTINIB |
| 10007662 | 10005522 | 1.83 | 102 | Palliative (P) | 2017-12-16 | 2017-12-17 | Cetuximab 14 day | N | N | 10430552 | TRIFLURIDINE + TIPIRACIL |
| 10007663 | 10005523 | 1.66 | null | Palliative (P) | 2019-08-23 | 2019-08-25 | DOCETAXEL + TRASTUZUMAB | N | N | 10430552 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB |
| 10007664 | 10005524 | 1.7 | 73 | Palliative (P) | 2018-02-26 | 2018-03-02 | Ipilimumab | 02 | N | 10435336 | CABOZANTINIB |
| 10007665 | 10005527 | 1.87 | 83.5 | Palliative (P) | 2019-07-25 | 2019-08-05 | Cyclophosphamide + Etoposide (PO) | 2 | N | 10436778 | ENRICH TRIAL |
| 10007666 | 10005528 | null | 86.65 | Curative (C) | 2019-04-16 | 2019-04-16 | Bortezomib (weekly) | null | N | 10437133 | VENETOCLAX |
| 10007667 | 10005529 | null | 78 | Palliative (P) | 2017-02-02 | 2017-02-02 | BENDAMUSTINE | N | N | 10437133 | DOCETAXEL + GEMCITABINE |
| 10007668 | 10005530 | 1.71 | 95.3 | Palliative (P) | 2018-07-31 | 2018-08-16 | Enzalutamide | 02 | Y | 10439991 | ECX |
| 10007669 | 10005533 | 1.69 | 51.5 | Not known (9) | 2016-11-27 | 2016-11-28 | Cetuximab 14 day | Y | null | 10441439 | CISPLATIN + PEMETREXED |
| 10007670 | 10005534 | null | 83.2 | Palliative (P) | 2017-11-22 | 2018-01-11 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | 10441739 | EVEROLIMUS |
| 10007671 | 10005535 | 1.77 | 75.6 | Palliative (P) | 2015-05-05 | 2015-05-05 | Enzalutamide | 2 | N | 10445721 | ABVD |
| 10007672 | 10005535 | 1.53 | 116.3 | Palliative (P) | 2019-01-24 | 2019-01-24 | EC | N | N | 10445721 | DOCETAXEL + TRASTUZUMAB |
| 10007673 | 10005540 | 1.81 | 80.6 | Curative (C) | 2018-10-20 | 2019-02-16 | IDARUBICIN | 02 | N | 10445767 | MPV |
| 10007674 | 10005541 | 0 | 78 | Palliative (P) | 2016-09-03 | 2016-09-22 | Cetuximab + FLUOROURACIL + FOLINIC ACID + IRINOTECAN | N | N | 10447462 | REMODL TRIAL |
| 10007675 | 10005541 | 1.72 | 73 | Palliative (P) | 2020-01-21 | 2020-02-07 | Pazopanib | N | N | 10447462 | OXALIPLATIN + RALTITREXED |
| 10007676 | 10005542 | 1.6 | 73.4 | Palliative (P) | 2017-01-26 | 2017-02-04 | Cisplatin + Vinorelbine (PO) | 2 | N | 10451037 | CAPECITABINE + CISPLATIN |
| 10007677 | 10007745 | 1.59 | 84 | Palliative (P) | 2018-06-15 | 2018-06-24 | CISPLATIN + VINORELBINE + RT | N | N | 10451896 | MITOMYCIN INTRAVESICULAR |
| 10007678 | 10005543 | 1.57 | 75.8 | Disease modification (D) | 2016-01-20 | 2016-02-10 | CETUXIMAB | N | N | 10454806 | IPILIMUMAB + NIVOLUMAB |
| 10007679 | 10005544 | 1.66 | 80.2 | Palliative (P) | 2018-09-23 | 2018-10-03 | FEC | N | N | 10454967 | METHOTREXATE INTRATHECAL |
| 10007680 | 10005544 | 1.82 | 51.8 | Palliative (P) | null | 2017-10-20 | Ipilimumab | N | N | 10454967 | NIVOLUMAB |
| 10007681 | 10005545 | 1.75 | 85.1 | Palliative (P) | 2016-07-09 | 2016-10-02 | CHOP R + METHOTREXATE | N | N | 10457159 | R-EPOCH |
| 10007682 | 10005545 | 1.51 | 0 | Disease modification (D) | 2014-10-12 | 2015-02-03 | Etoposide oral | N | N | 10457159 | OSIMERTINIB |
| 10007683 | 10005546 | 0 | 66 | Curative (C) | 2017-12-30 | 2017-12-30 | Docetaxel + Nintedanib | N | N | 10460803 | MELPHALAN |
| 10007684 | 10005546 | 1.74 | 78.4 | Palliative (P) | 2018-10-13 | 2018-11-25 | RIALTO TRIAL | 2 | Y | 10460803 | CISPLATIN + RT |
| 10007685 | 10005546 | 1.79 | 69.4 | Palliative (P) | 2018-01-17 | 2018-01-24 | GEFITINIB | N | N | 10460803 | FLUOROURACIL + MITOMYCIN + RT |
| 10007686 | 10005547 | null | 66.5 | null | 2017-01-28 | 2017-02-13 | VINORELBINE | 2 | N | 10462897 | EC |
| 10007687 | 10005548 | null | 93 | Neo-adjuvant (N) | 1983-11-02 | 2018-03-17 | Cetuximab + Radiotherapy Load | 02 | N | 10463889 | BORTEZOMIB + THALIDOMIDE |
| 10007688 | 10005549 | null | 0 | Curative (C) | 2016-01-05 | 2016-01-26 | CISPLATIN + GEMCITABINE | N | N | 10464205 | CETUXIMAB + IRINOTECAN + MDG |
| 10007689 | 10005549 | 1.85 | 73.6 | Palliative (P) | 2018-01-07 | 2018-02-10 | CISPLATIN + FLUOROURACIL + RT | N | N | 10464205 | FLUOROURACIL + MITOMYCIN + RT |
| 10007690 | 10005549 | 1.64 | 96.1 | Adjuvant (A) | 2015-08-29 | 2015-08-30 | CAV | 02 | N | 10464205 | CARBOPLATIN + PACLITAXEL + RT |
| 10007691 | 10007751 | null | null | Disease modification (D) | 2018-07-21 | 2018-07-28 | Cisplatin + Gemcitabine (D 1 & 8) | N | null | 10473371 | HCX |
| 10007692 | 10005552 | 0 | 80.7 | Disease modification (D) | 2019-04-19 | 2019-05-02 | OXALIPLATIN | N | Y | 10473566 | CYCLOPHOSPHAMIDE + ETOPOSIDE |
| 10007693 | 10005553 | 1.68 | 60.4 | Palliative (P) | 2015-10-12 | 2015-10-26 | DABRAFENIB + TRAMETINIB | 02 | N | 10474120 | NIVOLUMAB |
| 10007694 | 10005554 | null | 60.6 | Palliative (P) | 2019-06-24 | 2019-07-14 | Methotrexate intrathecal | 2 | Y | 10475222 | CHLORAMBUCIL + RITUXIMAB |
| 10007695 | 10005554 | 1.62 | 60.1 | Disease modification (D) | 2018-04-09 | 2018-09-03 | ABVD | 02 | N | 10475222 | METHOTREXATE HIGH DOSE |
| 10007696 | 10005555 | 1.78 | 71 | Palliative (P) | 2019-02-06 | 2019-02-09 | Cytarabine High Dose | 02 | N | 10476489 | BORTEZOMIB + PANOBINOSTAT |
| 10007697 | 10005558 | 1.87 | 80 | Curative (C) | 2018-07-31 | 2018-07-31 | Cabazitaxel | N | N | 10481046 | CAPECITABINE + IRINOTECAN |
| 10007698 | 10005559 | 1.73 | null | Palliative (P) | 2018-07-05 | 2018-07-11 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | N | N | 10482104 | CARBOPLATIN + PACLITAXEL + RT |
| 10007699 | 10007754 | 1.7 | null | null | 2018-11-08 | 2018-11-18 | FEC | N | Y | 10482233 | CHLORAMBUCIL + OBINUTUZUMAB |
| 10007700 | 10005560 | 1.6 | 91.4 | null | 2018-01-31 | 2018-03-09 | RUXOLITINIB | 02 | N | 10482233 | CHLORAMBUCIL |
| 10007701 | 10005560 | 1.77 | 70 | Palliative (P) | 2015-02-25 | 2015-09-18 | EOX | 02 | N | 10482233 | CETUXIMAB + IRINOTECAN + MDG |
| 10007702 | 10007756 | null | 80 | Disease modification (D) | null | 2017-09-11 | EOX | N | N | 10483915 | CETUXIMAB |
| 10007703 | 10005562 | 0 | 71 | null | 2016-03-28 | 2016-04-24 | Liposomal Doxorubicin (Caelyx) | N | N | 10484222 | IMATINIB |
| 10007704 | 10005563 | null | 85.3 | Adjuvant (A) | 2018-11-02 | 2018-12-28 | Cisplatin + Pemetrexed | N | N | 10486400 | CISPLATIN + GEMCITABINE |
| 10007705 | 10005563 | null | 92.2 | Palliative (P) | null | 2019-07-22 | VINORELBINE | N | N | 10486400 | TRIFLURIDINE + TIPIRACIL |
| 10007706 | 10005564 | 1.79 | 69.9 | Palliative (P) | 2019-07-19 | 2019-10-18 | Methotrexate intrathecal | 2 | N | 10488657 | CETUXIMAB + OXALIPLATIN + MDG |
| 10007707 | 10005564 | 1.82 | 88.15 | Disease modification (D) | 2017-01-29 | 2017-02-07 | GDP | 2 | N | 10488657 | CETUXIMAB + IRINOTECAN + MDG |
| 10007708 | 10005567 | 1.67 | null | Adjuvant (A) | 2016-08-31 | 2016-09-21 | VEPEMB | 02 | N | 10489910 | VEPEMB |
| 10007709 | 10005567 | null | null | Curative (C) | 2015-07-15 | 2017-01-28 | CARDAMON trial | N | null | 10489910 | CVD |
| 10007710 | 10005569 | 1.63 | 74.9 | Palliative (P) | 2016-03-26 | 2016-04-20 | CISPLATIN + ETOPOSIDE | 02 | N | 10491733 | CETUXIMAB + IRINOTECAN + MDG |